Bazaar India's new issue looks at collagen loss and skin laxity concerns tied to fast GLP-1 weight loss, and how beauty brands are responding.
Recap by typeshit. Post by @bazaarindia on Instagram.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Morse says bar and restaurant workers have seen younger adults drink less, framing it as a broad change in the alcohol industry.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
A Facebook post points to stories on how Ozempic has brought fresh tension over weight and appearance between relatives.
An AI chatbot answer lays out single, dual and triple agonists, noting Lilly's retatrutide adds the glucagon receptor and is still investigational.
Nausea hit 20% of users vs 6% on placebo, with other gut effects near placebo levels. A GP tells Medical News Today phase 3 data is still needed.
Loading…